Bugs & Drugs
I found that I was losing the plot about what was where! Here’s my quick guide to priority pathogens and pipeline reviews. Corrections and amends gratefully received.
Priority Pathogen / Threat Lists
- CDC 2019: Newsletter is here, report itself is here.
- WHO 2017: Newsletter is here, report itself is here.
- CDC 2013: Report itself is here.
- ESKAPE list 2008-9: The original papers are here:
- (link) Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-81.
- (link) Boucher HW et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009;48(1):1-12
- Comparative summary of all 4 priority pathogen lists as a PowerPoint deck is here.
- Please also see this newsletter for a further discussion of the priority pathogen lists as well as the idea of first- vs. best-in-class.
- Reviews by WHO
- Reviews by the Pew Trusts (all updated as of April 2020)
- Independent reviews
- Clinical pipeline: Theuretzbacher et al. Nat Rev Microbiol 2020 (https://doi.org/10.1038/s41579-020-0340-0) is an extended commentary on the current pipeline by the group who did the WHO 2019 review.
- Clinical pipeline: Butler and Paterson, J Antibiot 2020 https://doi.org/10.1038/s41429-020-0291-8: Not open access, but you can view it online here.
- Commercial view of recently approved drugs: Alan Carr 2020: Newsletter is here. Alan’s regularly updated summary analyzes products approved in the US since 2009.
- Non-traditional products: Theuretzbacher and Piddock, Cell Host Microb 2019 (https://doi.org/10.1016/j.chom.2019.06.004) and Rex et al. Nat Commun 2019, https://doi.org/10.1038/s41467-019-11303-9: Focused reviews and discussions of non-traditional products. Go here for a newsletter about these two papers.
- Preclinical pipeline: Theuretzbacher et al. Nat Rev Microbiol 2019 (https://www.nature.com/articles/s41579-019-0288-0) surveys 400+ active preclinical programs.
Dear All, I know we are all really, really tired of COVID but it certainly is not tired of us! The recent news on the vaccine front is exciting, but my personal guess is that we’re unlikely to see large-scale gatherings during 2021 … it’s just going to take time to get everybody vaccinated. So,
Dear All, Today we have a bit of a potpourri for WAAW (World Antibiotic Awareness Week). Lots of good stuff… In the new meetings category, we have two meetings for investors seeking social impact: 23 Nov 2020 (online, 6-7p CET): Webinar sponsored by Access to Medicine Foundation (ATM) entitled “The Materiality of Superbugs: Investor Action